Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma
Main Article Content
Keywords
31-GEP, cutaneous melanoma, SLNB
References
1. Thomas, D. C. et al. Ann Surg Oncol 26, 2254–2262 (2019).
2.Jones, E. L. et al. JAMA surgery 148, 456–61 (2013).
3. Greenhaw, et al. Dermatol Surg 44, 1494–1500 (2018).
4. O’Connell, E. et al. Mel Research 26, 66-70 (2016).
5. Luke et al. Lancet, 399, 1718-1729 (2022).
6. Hsueh, E. C. et al. JCO Precision Oncology 5, 589–601 (2021).
7. Vetto, J. T. et al. Future Oncology 15, 1207–1217 (2019).
8. Podlipnik, S. et al. J Eur Acad Dermatol Venereol 33, 857–862 (2019).
9. Dillon, L. D. et al. SKIN J Cutaneous Med 2, 111–121 (2018).
10. Berger, A. C. et al. Curr Med Res Opin 32, 1599–1604 (2016).
2.Jones, E. L. et al. JAMA surgery 148, 456–61 (2013).
3. Greenhaw, et al. Dermatol Surg 44, 1494–1500 (2018).
4. O’Connell, E. et al. Mel Research 26, 66-70 (2016).
5. Luke et al. Lancet, 399, 1718-1729 (2022).
6. Hsueh, E. C. et al. JCO Precision Oncology 5, 589–601 (2021).
7. Vetto, J. T. et al. Future Oncology 15, 1207–1217 (2019).
8. Podlipnik, S. et al. J Eur Acad Dermatol Venereol 33, 857–862 (2019).
9. Dillon, L. D. et al. SKIN J Cutaneous Med 2, 111–121 (2018).
10. Berger, A. C. et al. Curr Med Res Opin 32, 1599–1604 (2016).